{{Distinguish|depramine}}
{{Drugbox
| verifiedrevid = 477166380
| IUPAC_name = 3-(10,11-dihydro-5''H''-dibenzo[''b'',''f'']azepin-5-yl)-''N''-methylpropan-1-amine
| image = Desipramine.svg
| alt = Skeletal formula of desipramine
| width = 200px
| image2 = Desipramine-3D-balls.png
| alt2 = Ball-and-stick model of the desipramine molecule
| width2 = 225px
<!--Clinical data-->
| tradename = Norpramin, Pertofrane, others
| Drugs.com = {{drugs.com|monograph|desipramine-hydrochloride}}
| MedlinePlus = a682387
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = [[Oral administration|Oral]], [[intramuscular injection]]
<!--Pharmacokinetic data-->
| bioavailability = 60–70%<ref name="LemkeWilliams2012">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA588|date=24 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-345-0|pages=588–}}</ref>
| protein_bound = 91%<ref name="LemkeWilliams2012" />
| metabolism = [[Liver]] ([[CYP2D6]])<ref name=clinp>{{cite journal|last1=Sallee|first1=FR|last2=Pollock|first2=BG|title=Clinical pharmacokinetics of imipramine and desipramine.|journal=Clinical Pharmacokinetics|date=May 1990|volume=18|issue=5|pages=346–64|doi=10.2165/00003088-199018050-00002|pmid=2185906}}</ref>
| elimination_half-life = 12–30 hours<ref name="LemkeWilliams2012" />
| excretion = [[Urine]] (70%), [[feces]]<ref name="LemkeWilliams2012" />
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50-47-5
| CAS_supplemental = <br />58-28-6 ([[hydrochloride]])<br />62265-06-9 ([[dibudinate]])
| ATC_prefix = N06
| ATC_suffix = AA01
| PubChem = 2995
| IUPHAR_ligand = 2399
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01151
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2888
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = TG537D343B
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07791
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 47781
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 72
| synonyms = Desmethylimipramine; Norimipramine; EX-4355; G-35020; JB-8181; NSC-114901<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="Drugs.com" />
<!--Chemical data-->
| C=18 | H=22 | N=2
| molecular_weight = 266.381 g/mol
| SMILES = c1cc3c(cc1)CCc2c(cccc2)N3CCCNC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HCYAFALTSJYZDH-UHFFFAOYSA-N
}}

'''Desipramine''', sold under the brand name '''Norpramin''' and '''Pertofrane''' among others, is a [[tricyclic antidepressant]] (TCA) which is used in the treatment of [[depression (mood)|depression]].<ref name="GG">{{cite book | isbn = 978-0-07-162442-8 | title = [[Goodman and Gilman's The Pharmacological Basis of Therapeutics]] | edition = 12th |author1=Brunton, L |author2=Chabner, B |author3=Knollman, B | year = 2010 | publisher = McGraw-Hill Professional | location = New York }}</ref> It acts as a relatively selective [[norepinephrine reuptake inhibitor]], though it does also have other activities such as weak [[serotonin reuptake inhibitor]]y, [[alpha-1 blocker|α<sub>1</sub>-blocking]], [[antihistamine]], and [[anticholinergic]] effects. The drug is not considered a first-line treatment for depression since the introduction of [[selective serotonin reuptake inhibitor]] (SSRI) [[antidepressant]]s, which have fewer [[side effect]]s and are safer in [[overdose]].

==Medical uses==
Desipramine is primarily used for the treatment of depression.<ref name = GG/> It may also be useful to treat symptoms of [[attention-deficit hyperactivity disorder]] (ADHD).<ref>{{cite journal|last1=Ghanizadeh|first1=A|title=A systematic review of the efficacy and safety of desipramine for treating ADHD.|journal=Current Drug Safety|date=July 2013|volume=8|issue=3|pages=169–74|doi=10.2174/15748863113089990029|pmid=23914752}}</ref> Evidence of benefit is only in the short term and with concerns of side effects its overall usefulness is not clear.<ref>{{cite journal|last1=Otasowie|first1=J|last2=Castells|first2=X|last3=Ehimare|first3=UP|last4=Smith|first4=CH|title=Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.|journal=The Cochrane database of systematic reviews|date=Sep 19, 2014|volume=9|pages=CD006997|pmid=25238582|doi=10.1002/14651858.CD006997.pub2}}</ref> Desipramine at very low doses is also used to help reduce the pain associated with [[functional dyspepsia]].<ref>http://www.uptodate.com/contents/upset-stomach-functional-dyspepsia-in-adults-beyond-the-basics</ref> It has also been tried, albeit with little evidence of effectiveness, in the treatment of [[cocaine dependence]].<ref>{{cite journal|last1=Pani|first1=PP|last2=Trogu|first2=E|last3=Vecchi|first3=S|last4=Amato|first4=L|title=Antidepressants for cocaine dependence and problematic cocaine use.|journal=The Cochrane Database of Systematic Reviews|date=December 2011|issue=12|pages=CD002950|doi=10.1002/14651858.CD002950.pub3|pmid=22161371|url=http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002950.pub3/full}}</ref> Evidence for usefulness in [[neuropathic pain]] is also poor.<ref name="pmid25246131">{{cite journal | vauthors = Hearn L, Moore RA, Derry S, Wiffen PJ, Phillips T | title = Desipramine for neuropathic pain in adults | journal = Cochrane Database Syst Rev | volume = | issue = 9 | pages = CD011003 | year = 2014 | pmid = 25246131 | doi = 10.1002/14651858.CD011003.pub2 | url = }}</ref>

==Side effects==
Desipramine tends to be less [[sedation|sedating]] than other TCAs and tends to produce fewer [[anticholinergic]] effects like [[dry mouth]], [[constipation]], [[urinary retention]], [[blurred vision]], and [[cognitive deficit|cognitive]]/[[memory impairment]].<ref name = MD>{{cite web|title=Desipramine Hydrochloride|work=Martindale: The Complete Drug Reference|publisher=Pharmaceutical Press|location=London, UK|date=13 December 2013|accessdate=17 July 2014|url=https://www.medicinescomplete.com/mc/martindale/current/2509-y.htm}}</ref>

==Overdose==
{{Main|Tricyclic antidepressant overdose}}

Desipramine is particularly toxic in cases of overdose, compared to other antidepressants.<ref>{{cite journal|last1=White|first1=N|last2=Litovitz|first2=T|last3=Clancy|first3=C|title=Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.|journal=Journal of Medical Toxicology|date=December 2008|volume=4|issue=4|pages=238–50|doi=10.1007/BF03161207|pmid=19031375|pmc=3550116}}</ref> Any overdose or suspected overdose of desipramine is considered to be a medical emergency and can result in death without prompt medical intervention.

==Pharmacology==

===Pharamcodynamics===
{{See also|Pharmacology of antidepressants|Tricyclic antidepressant#Binding profiles}}
{| class="wikitable floatleft" style="font-size:small;"
|+ Desipramine<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 14 August 2017 | url = https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=desipramine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! K<sub>i</sub> (nM) !! Species !! Ref
|-
| '''{{abbrlink|SERT|Serotonin transporter}}''' || '''17.6–163''' || '''Human''' || <ref name="pmid9537821">{{cite journal | vauthors = Tatsumi M, Groshan K, Blakely RD, Richelson E | title = Pharmacological profile of antidepressants and related compounds at human monoamine transporters | journal = Eur. J. Pharmacol. | volume = 340 | issue = 2-3 | pages = 249–58 | year = 1997 | pmid = 9537821 | doi = | url = }}</ref><ref name="pmid9400006">{{cite journal | vauthors = Owens MJ, Morgan WN, Plott SJ, Nemeroff CB | title = Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites | journal = J. Pharmacol. Exp. Ther. | volume = 283 | issue = 3 | pages = 1305–22 | year = 1997 | pmid = 9400006 | doi = | url = }}</ref>
|-
| '''{{abbrlink|NET|Norepinephrine transporter}}''' || '''0.63–3.5''' || '''Human''' || <ref name="pmid9537821" /><ref name="pmid9400006" />
|-
| {{abbrlink|DAT|Dopamine transporter}} || 3,190 || Human || <ref name="pmid9537821" />
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || ≥6,400 || Human || <ref name="pmid7855217" /><ref name="pmid3816971">{{cite journal | vauthors = Wander TJ, Nelson A, Okazaki H, Richelson E | title = Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro | journal = Eur. J. Pharmacol. | volume = 132 | issue = 2-3 | pages = 115–21 | year = 1986 | pmid = 3816971 | doi = | url = }}</ref>
|-
| '''[[5-HT2A receptor|5-HT<sub>2A</sub>]]''' || '''115–350''' || '''Human''' || <ref name="pmid7855217" /><ref name="pmid3816971" />
|-
| [[5-HT2C receptor|5-HT<sub>2C</sub>]] || 244–748 || Rat || <ref name="pmid8876023">{{cite journal | vauthors = Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J | title = Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor | journal = Psychopharmacology | volume = 126 | issue = 3 | pages = 234–40 | year = 1996 | pmid = 8876023 | doi = | url = }}</ref><ref name="pmid9686407">{{cite journal | vauthors = Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS | title = Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications | journal = NIDA Res. Monogr. | volume = 178 | issue = | pages = 440–66 | year = 1998 | pmid = 9686407 | doi = | url = }}</ref>
|-
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || ≥2,500 || Rodent || <ref name="pmid9686407" /><ref name="pmid2533080">{{cite journal | vauthors = Schmidt AW, Hurt SD, Peroutka SJ | title = '[3H]quipazine' degradation products label 5-HT uptake sites | journal = Eur. J. Pharmacol. | volume = 171 | issue = 1 | pages = 141–3 | year = 1989 | pmid = 2533080 | doi = | url = }}</ref>
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || >1,000 || Rat || <ref name="pmid8394362">{{cite journal | vauthors = Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR | title = Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype | journal = J. Biol. Chem. | volume = 268 | issue = 24 | pages = 18200–4 | year = 1993 | pmid = 8394362 | doi = | url = }}</ref>
|-
| '''[[Alpha-1 adrenergic receptor|α<sub>1</sub>]]''' || '''23–130''' || '''Human''' || <ref name="pmid7855217" /><ref name="pmid6086881" /><ref name="pmid9400006" />
|-
| [[Alpha-2 adrenergic receptor|α<sub>2</sub>]] || ≥1,379 || Human || <ref name="pmid7855217" /><ref name="pmid6086881" /><ref name="pmid9400006" />
|-
| [[Beta-adrenergic receptor|β]] || ≥1,700 || Rat || <ref name="pmid3790168">{{cite journal | vauthors = Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB | title = Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative | journal = Biochem. Pharmacol. | volume = 35 | issue = 24 | pages = 4493–7 | year = 1986 | pmid = 3790168 | doi = | url = }}</ref><ref name="pmid10379421">{{cite journal | vauthors = Sánchez C, Hyttel J | title = Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding | journal = Cell. Mol. Neurobiol. | volume = 19 | issue = 4 | pages = 467–89 | year = 1999 | pmid = 10379421 | doi = | url = }}</ref>
|-
| [[Dopamine D1 receptor|D<sub>1</sub>]] || 5,460 || Human || <ref name="pmid17850785">{{cite journal | vauthors = Deupree JD, Montgomery MD, Bylund DB | title = Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram | journal = Eur. J. Pharmacol. | volume = 576 | issue = 1-3 | pages = 55–60 | year = 2007 | pmid = 17850785 | pmc = 2231336 | doi = 10.1016/j.ejphar.2007.08.017 | url = }}</ref>
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || 3,400 || Human || <ref name="pmid7855217" /><ref name="pmid6086881" />
|-
| '''[[Histamine H1 receptor|H<sub>1</sub>]]''' || '''60–110''' || '''Human''' || <ref name="pmid7855217">{{cite journal | vauthors = Cusack B, Nelson A, Richelson E | title = Binding of antidepressants to human brain receptors: focus on newer generation compounds | journal = Psychopharmacology | volume = 114 | issue = 4 | pages = 559–65 | year = 1994 | pmid = 7855217 | doi = | url = }}</ref><ref name="pmid6086881">{{cite journal | vauthors = Richelson E, Nelson A | title = Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro | journal = J. Pharmacol. Exp. Ther. | volume = 230 | issue = 1 | pages = 94–102 | year = 1984 | pmid = 6086881 | doi = | url = }}</ref><ref name="pmid22033803">{{cite journal | vauthors = Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R | title = Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics | journal = Naunyn Schmiedebergs Arch. Pharmacol. | volume = 385 | issue = 2 | pages = 145–70 | year = 2012 | pmid = 22033803 | doi = 10.1007/s00210-011-0704-0 | url = }}</ref>
|-
| [[Histamine H2 receptor|H<sub>2</sub>]] || 1,550 || Human || <ref name="pmid22033803" />
|-
| [[Histamine H3 receptor|H<sub>3</sub>]] || >100,000 || Human || <ref name="pmid22033803" />
|-
| [[Histamine H4 receptor|H<sub>4</sub>]] || 9,550 || Human || <ref name="pmid22033803" />
|-
| '''{{abbrlink|mACh|Muscarinic acetylcholine receptor}}''' || '''66–198''' || '''Human''' || <ref name="pmid7855217" /><ref name="pmid6086881" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]]''' || '''110''' || '''Human''' || <ref name="pmid8100134">{{cite journal |vauthors=Stanton T, Bolden-Watson C, Cusack B, Richelson E |title=Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics |journal=Biochem. Pharmacol. |volume=45 |issue=11 |pages=2352–4 |year=1993 |pmid=8100134 |doi= |url=}}</ref>
|-
| &nbsp;&nbsp;[[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]] || 540 || Human || <ref name="pmid8100134" />
|-
| &nbsp;&nbsp;[[Muscarinic acetylcholine receptor M3|M<sub>3</sub>]] || 210 || Human || <ref name="pmid8100134" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M4|M<sub>4</sub>]]''' || '''160''' || '''Human''' || <ref name="pmid8100134" />
|-
| '''&nbsp;&nbsp;[[Muscarinic acetylcholine receptor M5|M<sub>5</sub>]]''' || '''143''' || '''Human''' || <ref name="pmid8100134" />
|-
| [[Sigma-1 receptor|σ<sub>1</sub>]] || 1,990–4,000 || Rodent || <ref name="pmid2877462">{{cite journal | vauthors = Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JF | title = 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 83 | issue = 22 | pages = 8784–8 | year = 1986 | pmid = 2877462 | pmc = 387016 | doi = | url = }}</ref><ref name="pmid20373470">{{cite journal | vauthors = Hindmarch I, Hashimoto K | title = Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered | journal = Hum Psychopharmacol | volume = 25 | issue = 3 | pages = 193–200 | year = 2010 | pmid = 20373470 | doi = 10.1002/hup.1106 | url = }}</ref>
|-
| [[Sigma-2 receptor|σ<sub>2</sub>]] || ≥1,611 || Rat || <ref name="PDSP" /><ref name="pmid20373470" />
|- class="sortbottom"
| colspan="4" style="width: 1px;" | Values are K<sub>i</sub> (nM). The smaller the value, the more strongly the drug binds to the site.
|}

Desipramine is a very potent and relatively selective [[norepinephrine reuptake inhibitor]] (NRI), which is thought to enhance [[noradrenergic]] [[neurotransmission]].<ref name="MartinVolkmar2007" /><ref name="pmid6384207">{{cite journal | vauthors = Janowsky DS, Byerley B | title = Desipramine: an overview | journal = J Clin Psychiatry | volume = 45 | issue = 10 Pt 2 | pages = 3–9 | year = 1984 | pmid = 6384207 | doi = | url = }}</ref> Based on one study, it has the highest affinity for the [[norepinephrine transporter]] (NET) of any other TCA,<ref name="pmid9537821" /> and is said to be the most noradrenergic<ref name="Curtin2016" /> and the most selective for the NET of the TCAs.<ref name="MartinVolkmar2007">{{cite book|author1=Andrés Martin|author2=Fred R. Volkmar|author3=Melvin Lewis|title=Lewis's Child and Adolescent Psychiatry: A Comprehensive Textbook|url=https://books.google.com/books?id=s9Jdn43iac8C&pg=PA764|year=2007|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6214-4|pages=764–}}</ref> The observed effectiveness of desipramine in the treatment of ADHD was the basis for the development of the selective NRI [[atomoxetine]] and its use in ADHD.<ref name="MartinVolkmar2007" />

Desipramine has the weakest [[antihistamine]] and [[anticholinergic]] effects of the TCAs.<ref name="GoldCarman1984">{{cite book|author1=Mark S. Gold|author2=John S. Carman|author3=R. Bruce Lydiard|title=Advances in Psychopharmacology|url=https://books.google.com/books?id=wwP1iOanWAAC&pg=PA98|date=2 July 1984|publisher=CRC Press|isbn=978-0-8493-5680-3|pages=98–}}</ref><ref name="Curtin2016">{{cite book|author=Catherine Curtin|title=Pain Management, An Issue of Hand Clinics, E-Book|url=https://books.google.com/books?id=TeGZCwAAQBAJ&pg=PA55|date=19 January 2016|publisher=Elsevier Health Sciences|isbn=978-0-323-41691-7|pages=55–}}</ref><ref name="BaylessDiehl2005">{{cite book|author1=Theodore M. Bayless|author2=Anna Diehl|title=Advanced Therapy in Gastroenterology and Liver Disease|url=https://books.google.com/books?id=XR-Jsxz0qRwC&pg=PA263|year=2005|publisher=PMPH-USA|isbn=978-1-55009-248-6|pages=263–}}</ref> It tends to be slightly [[psychostimulant|activating/stimulating]] rather than [[sedative|sedating]], unlike most others TCAs.<ref name="Curtin2016" /> Whereas other TCAs are useful for treating [[insomnia]], desipramine can cause insomnia as a side effect due to its activating properties.<ref name="Curtin2016" /> The drug is also not associated with [[weight gain]], in contrast to many other TCAs.<ref name="Curtin2016" /> Secondary amine TCAs like desipramine and [[nortriptyline]] have a lower risk of [[orthostatic hypotension]] than other TCAs,<ref name="Leigh2012">{{cite book|author=Hoyle Leigh|title=Biopsychosocial Approaches in Primary Care: State of the Art and Challenges for the 21st Century|url=https://books.google.com/books?id=5kcIBgAAQBAJ&pg=PA108|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4615-5957-3|pages=108–}}</ref><ref name="HalesYudofsky2011">{{cite book|author1=Robert E. Hales|author2=Stuart C. Yudofsky|author3=Glen O. Gabbard|title=Essentials of Psychiatry|url=https://books.google.com/books?id=Hf50vMMMv_wC&pg=PA468|year=2011|publisher=American Psychiatric Pub|isbn=978-1-58562-933-6|pages=468–}}</ref> although desipramine can still cause moderate orthostatic hypotension.<ref name="Rakel2007">{{cite book|author=Robert E. Rakel|title=Textbook of Family Medicine E-Book|url=https://books.google.com/books?id=ntcoDwAAQBAJ&pg=PA313|date=May 2007|publisher=Elsevier Health Sciences|isbn=978-1-4377-2190-4|pages=313–}}</ref>

===Pharmacokinetics===
Desipramine is the major [[metabolite]] of [[imipramine]] and [[lofepramine]].<ref name="pmid2891742">{{cite journal | vauthors = Leonard BE | title = A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review | journal = Int Clin Psychopharmacol | volume = 2 | issue = 4 | pages = 281–97 | year = 1987 | pmid = 2891742 | doi = | url = }}</ref>

==Chemistry==
Desipramine is a [[tricyclic compound]], specifically a [[dibenzazepine]], and possesses three [[ring (chemistry)|ring]]s fused together with a [[side chain]] attached in its [[chemical structure]].<ref name="Ritsner2013">{{cite book|author=Michael S Ritsner|title=Polypharmacy in Psychiatry Practice, Volume I: Multiple Medication Use Strategies|url=https://books.google.com/books?id=jy-LMZU7338C&pg=PA270|date=15 February 2013|publisher=Springer Science & Business Media|isbn=978-94-007-5805-6|pages=270–271}}</ref> Other dibenzazepine TCAs include [[imipramine]] (''N''-methyldesipramine), [[clomipramine]], [[trimipramine]], and [[lofepramine]] (''N''-(4-chlorobenzoylmethyl)desipramine).<ref name="Ritsner2013" /><ref name="LemkeWilliams2008">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA580|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6879-5|pages=580–}}</ref> Desipramine is a [[secondary amine]] TCA, with its ''N''-[[methylation|methylated]] [[parent compound|parent]] imipramine being a [[tertiary amine]].<ref name="CutlerSramek1994">{{cite book|author1=Neal R. Cutler|author2=John J. Sramek|author3=Prem K. Narang|title=Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology|url=https://books.google.com/books?id=ncRXa8Dq88QC&pg=PA160|date=20 September 1994|publisher=John Wiley & Sons|isbn=978-0-471-95052-3|pages=160–}}</ref><ref name="AnzenbacherZanger2012">{{cite book|author1=Pavel Anzenbacher|author2=Ulrich M. Zanger|title=Metabolism of Drugs and Other Xenobiotics|url=https://books.google.com/books?id=f-XHh17NfwgC&pg=PA302|date=23 February 2012|publisher=John Wiley & Sons|isbn=978-3-527-64632-6|pages=302–}}</ref> Other secondary amine TCAs include [[nortriptyline]] and [[protriptyline]].<ref name="Anthony2002">{{cite book|author=Patricia K. Anthony|title=Pharmacology Secrets|url=https://books.google.com/books?id=_QQsj3PAUrEC&pg=PA39|year=2002|publisher=Elsevier Health Sciences|isbn=1-56053-470-2|pages=39–}}</ref><ref name="CowenHarrison2012">{{cite book|author1=Philip Cowen|author2=Paul Harrison|author3=Tom Burns|title=Shorter Oxford Textbook of Psychiatry|url=https://books.google.com/books?id=Y1DtSGq-LnoC&pg=PA532|date=9 August 2012|publisher=OUP Oxford|isbn=978-0-19-162675-3|pages=532–}}</ref> The [[chemical name]] of desipramine is 3-(10,11-dihydro-5''H''-dibenzo[''b'',''f'']azepin-5-yl)-''N''-methylpropan-1-amine and its [[free base]] form has a [[chemical formula]] of C<sub>18</sub>H<sub>22</sub>N<sub>2</sub> with a [[molecular weight]] of 266.381&nbsp;g/mol.<ref name="Elks2014" /> The drug is used commercially mostly as the [[hydrochloride]] [[salt (chemistry)|salt]]; the [[dibudinate]] salt is or has been used for [[intramuscular injection]] in [[Argentina]] (brand name Nebril) and the free base form is not used.<ref name="Elks2014" /><ref name="IndexNominum2000" /> The [[CAS Registry Number]] of the free base is 50-47-5, of the hydrochloride is 58-28-6, and of the dibudinate is 62265-06-9.<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="ChemIDplus">https://chem.nlm.nih.gov/chemidplus/rn/62265-06-9</ref>

==History==
Desipramine was developed by [[Geigy]].<ref name="pmid19557250">{{cite journal | vauthors = Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K | title = Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters | journal = Chem. Commun. (Camb.) | volume = | issue = 25 | pages = 3677–92 | year = 2009 | pmid = 19557250 | doi = 10.1039/b903035m | url = }}</ref> It first appeared in the literature in 1959 and was patented in 1962.<ref name="pmid19557250" /> The drug was first introduced for the treatment of depression in 1963 or 1964.<ref name="pmid19557250" /><ref name="Dart2004">{{cite book|author=Richard C. Dart|title=Medical Toxicology|url=https://books.google.com/books?id=BfdighlyGiwC&pg=PA836|year=2004|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-2845-4|pages=836–}}</ref>

==Society and culture==

===Generic names===
''Desipramine'' is the [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}} and {{abbrlink|BAN|British Approved Name}}, while ''desipramine hydrochloride'' is its {{abbrlink|USAN|United States Adopted Name}}, {{abbrlink|USP|United States Pharmacopeia}}, {{abbrlink|BAN|British Approved Name}}, and {{abbrlink|JAN|Japanese Accepted Name}}.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA363|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=363–}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA304|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=304–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA94|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=94–}}</ref><ref name="Drugs.com">https://www.drugs.com/international/desipramine.html</ref> Its generic name in [[French language|French]] and its {{abbrlink|DCF|Dénomination Commune Française}} are ''désipramine'', in [[Spanish language|Spanish]] and [[Italian language|Italian]] and its {{abbrlink|DCIT|Denominazione Comune Italiana}} are ''desipramina'', in [[German language|German]] is ''desipramin'', and in [[Latin language|Latin]] is ''desipraminum''.<ref name="IndexNominum2000" /><ref name="Drugs.com" />

===Brand names===
Desipramine is or has been marketed throughout the world under a variety of brand names, including Irene, Nebril, '''Norpramin''', Pertofran, '''Pertofrane''', Pertrofran, and Petylyl among others.<ref name="IndexNominum2000" /><ref name="Drugs.com" />

==References==
{{Reflist|2}}

==External links==
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682387.html Desipramine - MedlinePlus]

{{Antidepressants}}
{{ADHD pharmacotherapies}}
{{Stimulants}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Histamine receptor modulators}}
{{Ion channel modulators}}
{{Monoamine reuptake inhibitors}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Alpha-1 blockers]]
[[Category:Amines]]
[[Category:Antihistamines]]
[[Category:Dibenzazepines]]
[[Category:Human drug metabolites]]
[[Category:Muscarinic antagonists]]
[[Category:Norepinephrine reuptake inhibitors]]
[[Category:Serotonin antagonists]]
[[Category:Sodium channel blockers]]
[[Category:Stimulants]]
[[Category:Tricyclic antidepressants]]